972 filings
Page 4 of 49
8-K
SNGX
Soligenix Inc
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
SNGX
Soligenix Inc
19 Apr 23
Correspondence with SEC
12:00am
8-K
SNGX
Soligenix Inc
14 Apr 23
Other Events
8:33am
8-K
SNGX
Soligenix Inc
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
UPLOAD
SNGX
Soligenix Inc
7 Apr 23
Letter from SEC
12:00am
S-1
SNGX
Soligenix Inc
IPO registration
31 Mar 23
5:01pm
10-K
2022 FY
SNGX
Soligenix Inc
Annual report
31 Mar 23
4:31pm
8-K
SNGX
Soligenix Inc
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
SNGX
Soligenix Inc
14 Feb 23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
7:46am
8-K
SNGX
Soligenix Inc
9 Feb 23
Soligenix Announces Reverse Stock Split
7:45am
DEFA14A
SNGX
Soligenix Inc
11 Jan 23
Additional proxy soliciting materials
8:02am
8-K
SNGX
Soligenix Inc
11 Jan 23
Other Events
8:00am
DEF 14A
SNGX
Soligenix Inc
Definitive proxy
6 Jan 23
4:04pm
8-K
SNGX
Soligenix Inc
27 Dec 22
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
4:25pm
8-A12G
SNGX
Soligenix Inc
27 Dec 22
Registration of securities
4:05pm
PRE 14A
SNGX
Soligenix Inc
Preliminary proxy
23 Dec 22
4:09pm
8-K
SNGX
Soligenix Inc
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
SNGX
Soligenix Inc
19 Dec 22
Other Events
8:00am
8-K
SNGX
Soligenix Inc
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am
4
SNGX
Soligenix Inc
9 Dec 22
SOLIGENIX / Richard Straube ownership change
4:09pm